Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levothyroxine Supplementation for Heart Transplant Recipients
NCT06428097Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of levothyroxine sodium in cardiac allograft failure (CAF) and Infection after heart transplant (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Number of participants who receive vasopressor use at 35 months. Started Mar 2024; status: recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
cardiac allograft failure (CAF)Infection after heart transplant
Beyond the preview
Go deeper on NCT06428097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428097.